<bill session="110" type="s" number="3409" updated="2009-01-09T19:00:19-05:00">
	<status><introduced date="1217476800" datetime="2008-07-31"/></status>

	<introduced date="1217476800" datetime="2008-07-31"/>
	<titles>
		<title type="short" as="introduced">Drug and Device Accountability Act of 2008</title>
		<title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes.</title>
	</titles>
	<sponsor id="300059"/>
	<cosponsors>
		<cosponsor id="300048" joined="2008-07-31"/>
	</cosponsors>
	<actions>
		<action date="1217476800" datetime="2008-07-31"><text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text></action>
	</actions>
	<committees>

	</committees>
	<relatedbills>

	</relatedbills>
	<subjects>

	</subjects>
	<amendments>

	</amendments>
	<summary>
	7/31/2008--Introduced.<br/>Drug and Device Accountability Act of 2008 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to deem a drug or device to be misbranded unless certain conditions related to registration of establishments, identification of prior transactions, labeling for country of manufacture, and provision of required information on importation are met.<br/>Includes in the definition of &quot;drug&quot; a precursor ingredient.<br/>Repeals the registration exemption for manufacturers of harmless inactive ingredients that become components of drugs.<br/>Expands the information required to be included for registration of establishments.<br/>Deems a drug to be adulterated if certain conditions related to verification of identity and purity, identification of establishments, consistency with current manufacturing technologies, and conformity with good distribution and import practices are not met.<br/>Sets forth provisions governing importation of a drug. Sets forth required actions, including cessation of distribution, if there is a reasonable probability that a drug intended for human use would cause serious, adverse health consequences or death.<br/>Establishes actions manufacturers must take regarding any defective drug.<br/>Sets forth additional required certifications for submissions related to drugs and devices regarding accuracy of information submitted and personal knowledge of such information.<br/>Establishes whistleblower protection for employees providing information regarding a drug, biological product, or device.<br/>Directs the Secretary of Health and Human Services to establish and maintain a corps of inspectors dedicated to inspections of foreign establishments and foreign facilities.<br/>Authorizes the Secretary to conduct investigations, subpoena witnesses, and compel attendance of witnesses as necessary to carry out authority under the FFDCA or provisions governing the regulation of biological products.<br/>Requires reports to the Secretary regarding certain civil actions involving a regulated product.<br/>
	</summary>
</bill>
